Home » CoreRx selects Xcelodose to enhance product development
CoreRx selects Xcelodose to enhance product development
November 2, 2011
CoreRx, a contract development and manufacturing organization, has enhanced its offering by adding an Xcelodose precision powder micro-dosing system to its product development capabilities in response to client requirements for preclinical and early phase clinical GMP supply. The Xcelodose decreases processing time and API use – generating significant cost savings to clients.
For simple formulations of API or powder-in-capsule, the Xcelodose system can significantly reduce processing time and API usage resulting in cost savings when compared to hand-filling options. “While CoreRx has always offered API in capsule, we now see examples of some clients maintaining this approach through to phase II studies in an attempt to compress their overall development timelines, requiring significant quantities of capsules for which an automated solution is best. CoreRx is the only CRO in the world with a full set of Xcelodose change parts all the way down to size 9," said Mark Licarde, CoreRx’s VP of manufacturing.
The Xcelodose system, manufactured by Capsugel, is a precision powder micro-doser and automated encapsulator that has the ability to fill formulations or API directly into capsules with a high level of accuracy. The Xcelodose system can dispense amounts as low as 100 micrograms and up to 100 milligrams and beyond, into capsules from size 00 to size 9. Dosing directly into capsules can reduce the amount of API required. Additionally, the unit minimizes overall development time by simplifying analytical and stability protocols.
Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials
Learn More Here